SCHEMBL20152895

SCHEMBL20152895

Cc1ccc(/C=C/CO)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
CYP3A4 P08684 1/20 0.46
RECQL P46063 1/20 0.46
HDAC1 Q13547 5/20 0.38
HDAC3 O15379 4/20 0.38
HDAC2 Q92769 4/20 0.38
ADRA2A P08913 2/20 0.36
ADRA2B P18089 2/20 0.36
ADRA2C P18825 2/20 0.36
RHOA P61586 1/20 0.35
PADI4 Q9UM07 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA7 P36544 1/20 0.34
CHRNA4 P43681 1/20 0.34
MEN1 O00255 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10193818 0.82 HDAC1 (0.36) HDAC1HDAC3HDAC2ADRA2AADRA2B
Hydrochloric Acid SCHEMBL7292521 0.78 HDAC3 (0.38) HDAC1HDAC3HDAC2ADRA2AADRA2B
Hydrochloric Acid SCHEMBL9871265 0.78 HDAC3 (0.38) HDAC1HDAC3HDAC2ADRA2AADRA2B
SCHEMBL12805682 0.78 PAM (0.55) ALDH1A1HDAC1HDAC3HDAC2PADI4
SCHEMBL17787989 0.78 HDAC1 (0.46) ALDH1A1HDAC1HDAC3HDAC2PADI4
SCHEMBL12074867 0.78 PAM (0.55) ALDH1A1HDAC1HDAC3HDAC2PADI4
SCHEMBL6559246 0.77 HDAC3 (0.39) HDAC1HDAC3HDAC2ADRA2AADRA2B
SCHEMBL4303773 0.77 APLNR (0.43) ALDH1A1CYP3A4HDAC1ADRA2AADRA2B
SCHEMBL5253130 0.77 ALDH1A1 (0.41) ALDH1A1CYP3A4RECQLRHOAPADI4
SCHEMBL5253126 0.77 ALDH1A1 (0.41) ALDH1A1CYP3A4RECQLRHOAPADI4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180134665-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134665-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 ALDH1A1 1542/4885CYP3A4 2069/4885RECQL 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.